Physician profile
Scott M Ross
NPI 1417944349
$478.49
in general payments reported to CMS, 2019-2025
15 companies · $42.23 in 2025
The $42.23 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.69 · 2020: $35.10 · 2021: $30.42 · 2022: $87.96 · 2023: $171 · 2024: $90.12 · 2025: $42.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $303.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $59.64 | 2022-2024 | Sotyktu |
| Lilly USA, LLC | $56.24 | 2022-2023 | Taltz, Olumiant |
| Genzyme Corporation | $51.23 | 2021-2023 | |
| Leo Pharma INC. | $42.96 | 2024-2025 | Adbry |
| Abbvie INC. | $42.76 | 2022-2024 | |
| Incyte Corporation | $42.12 | 2022-2023 | Opzelura |
| Janssen Biotech, INC. | $37.20 | 2020-2023 | Remicade, Simponi, Stelara |
| Sun Pharmaceutical Industries INC. | $25.03 | 2021-2025 | |
| Dermira, INC. | $21.69 | 2019 | |
| Organon LLC | $19.78 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.77 | 2020 | |
| Mylan Institutional INC. | $16.95 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $16.70 | 2023 | Dupixent |
| Verrica Pharmaceuticals INC. | $13.51 | 2025 | Ycanth |
| Dermavant Sciences, INC. | $12.91 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.